Pharmacological antihyperglycemic therapy of type 2 diabetes mellitus: Update of the evidence-based guidelines of the German Diabetes Association;Medikamentöse antihyperglykämische therapie des diabetes mellitus typ2: Update der evidenzbasierten leitlinie der Deutschen Diabetes-Gesellschaft

Diabetologie und Stoffwechsel

Volumn 4, Issue 1, 2009, Pages 32-64

  Matthaei, Stephan ^a   Bierwirth, R ^c   Fritsche, A ^c   Gallwitz, B ^c   Haring H U ^c   Joost, H G ^c   Kellerer, M ^c   Kloos, C ^c   Kunt, T ^c   Nauck, M ^c   Schernthaner, G ^c   Siegel, E ^c   Thienel, F ^c   Scherbaum, W A ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIBORNURIDE; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIQUIDONE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG; VILDAGLIPTIN; VOGLIBOSE;

ABDOMINAL PAIN; ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIHYPERTENSIVE THERAPY; BEDTIME DOSAGE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTASIS; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EDEMA; EVIDENCE BASED MEDICINE; FLATULENCE; FRACTURE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAUNDICE; LACTIC ACIDOSIS; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PAIN; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 60149099934     PISSN: 18619002     EISSN: 18619010     Source Type: Journal    
DOI: 10.1055/s-0028-1098798     Document Type: Review

References (295)

1. Abraira C, Henderson WG, Colwell JA et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-579 Evidenzklasse Ib
2. Ahrén B, Gomis R, Standl E et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874- 2880 Evidenzklasse Ib
3. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206 Evidenzklasse Ia
4. Anderson JH, Brunelle RL, Keohane P et al. Mealtime treatment with an insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157: 1249-1255 Evidenzklasse IIa
5. Anfosso F, Chromiki N, Alessi M et al. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin. J Clin Invest 1993; 91: 2185-2193 Evidenzklasse IIa
6. Aschner P, Kipnes MS, Lunceford JK et al Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637 Evidenzklasse Ib
7. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188 Evidenzklasse Ib
8. Bachmann W, Lotz N, Mehnert H et al. Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial. Dtsch Med Wochenschr 1988; 113: 631-636 Evidenzklasse IIa
9. Bailey CJ, Bagdonas A, Rubes J et al. Rosiglitazone/Metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005; 27: 1548-1561 Evidenzklasse Ib
10. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579 Evidenzklasse IV
11. Bakris G, Viberti G, Weston WM et al. Rosglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension 2003; 17: 7-12 Evidenzklasse Ib
12. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999; 57: 921-930 Evidenzklasse IV
13. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-1470 Evidenzklasse IV
14. Baron AD, Eckel RH, Kolterman OG. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type-2-diabetics. Metabolism 1987; 36: 409-415 Evidenzklasse IIb
15. Baron AD, Neumann C. PROTECT Interim Results: A large multicenter study of patients with type-2 diabetes. Clinical Therapeutics 1997; 19: 282-295 Evidenzklasse IIa
16. Bergman AJ, Stevens C, Zhou Y et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72 Evidenzklasse Ib
17. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007; 76: 279-289 Evidenzklasse Ia
18. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447 Evidenzklasse IIb
19. Bolli G, Dotta F, Rochotte E et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82-90 Evidenzklasse Ib
20. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895 Evidenzklasse Ib
21. Braun D, Schönher U, Mitzkat HJ. Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinology and Metabolism 1996; 3: 275- 280 Evidenzklasse Ib
22. Bretzel RG, Nuber U, Landgraf W et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084 Evidenzklasse Ib
23. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628- 2635 Evidenzklasse Ib
24. Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139-153 Evidenzklasse IIb
25. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ. Influence of 16 week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled double blind study with placebo. Diab Metab 1996; 22: 201-202 Evidenzklasse IIa
26. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a metaanalysis. Diabetes Metab Rev 1995; 11: 557-562 Evidenzklasse Ia
27. Carey DG, Cowin GJ, Galloway GJ et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008-1015 Evidenzklasse Ib
28. Ceriello A, Johns D, Widel M et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266-272 Evidenzklasse Ib
29. Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-473 Evidenzklasse Ib
30. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabetes Care 1998; 21: 1659-1663 Evidenzklasse IIa
31. Charbonnel B, Karasik A, Liu J et al Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643 Evidenzklasse Ib
32. Charbonnel BH, Matthews DR, Schernthaner G et al. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2004; 22: 399-405 Evidenzklasse Ib
33. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935 Evidenzklasse Ib
34. Chiasson JL, Nathan DM, Josse RG et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190 Evidenzklasse Ib
35. Chiasson JL, Gomis R, Hanefeld M et al. Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: The STOP-NIDDM Trial. The Lancet 2002; 359: 2072- 2077 Evidenzklasse Ib
36. Chilcott J, Tappendenden P, Jones ML et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001; 23: 1792-1823 Evidenzklasse IV
37. Chow CC, Tsang LW, Sorensen JP et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-314 Evidenzklasse IIa
38. Chu J, Abbasi F, Lamendola C et al. Improvements in vascular and inflammatory markers in rosiglitazone-treated insulin-resistant subjects are independent of changes in insulin sensitivity or glycemic control. Diabetes 2003; 52: 325-OR Evidenzklasse IIb
39. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Reviews 1998; 6: 89-131 Evidenzklasse IV
40. Dabrowski M, Wahl P, Holmes WE et al. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001; 44: 747-756 Evidenzklasse IV
41. Dailey GE, Noor MA, Park JS et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-229 Evidenzklasse Ib
42. Danchin N, Charpentier G, Ledru F et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143-149 Evidenzklasse III
43. Davis SN, Johns D, Maggs D et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007; 30: 2767-2772 Evidenzklasse III
44. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100 Evidenzklasse Ib
45. DeFronzo R, Goodman AM. Efficacy of Metformin in NIDDM patients poorly controlled on diet alone or diet plus sulfonlyurea. N Engl J Med 1995; 333: 541-549 Evidenzklasse Ib
46. Dejager S, Razac S, Foley JE et al. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218-223 Evidenzklasse Ib
47. DeLeon MJ, Chandurkar V, Albert SG et al. Glucagon-like peptide-1 response in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 2002; 56: 101-106 Evidenzklasse II
48. Delgado H, Lehmann T, Bobbioni-Harsch E et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200 Evidenzklasse II
49. Del Prato S, Vigili de Kreutzenberg S, Riccio A et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. Diabetologia 1990; 33: 688-695 Evidenzklasse IIb
50. De Luis DA, Aller R, Terroba C et al. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 1844-1845 Evidenzklasse Ib
51. Derosa G, Cicero AFG, d'Angelo A et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-924 Evidenzklasse Ib
52. Derosa G, Gaddi AV, Ciccarelli L et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res 2005; 33: 284- 294 Evidenzklasse Ib
53. Derosa G, Gaddi AV, Piccinni MN et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 2005; 25: 637-645 Evidenzklasse Ib
54. Derosa G, Gaddi AV, Piccinni MN et al. Differential effect of glimepirid and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diab Obes Metab 2006; 8: 197-205 Evidenzklasse Ib
55. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 2007; 147: 578-581 Evidenzklasse I a
56. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996; 28: 426-429 Evidenzklasse Ib
57. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Eng J Med 2008; 358: 2630-2633 Evidenzklasse IV
58. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289 Evidenzklasse Ib
59. Draeger KE,Wernicke-Panten K, Lomp H-J et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28: 419-425 Evidenzklasse Ib
60. Dunn CJ, Faulds D. Nateglinide. Drugs 2000; 60: 607-615 Evidenzklasse IV
61. Dunning BE. Newnon-sulfonylurea insulin secretagogues. Exp Opin Invest Drugs 1997; 6: 1041-1048 Evidenzklasse IV
62. Ebeling P, Teppo AM, Koistinen HA et al. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 2001; 50: 283-287 Evidenzklasse Ib
63. Einhorn D, Rendell M, Rosenzweig J et al The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22: 1395-1409 Evidenzklasse Ib
64. Emanuele N, Azad N, Abraira C et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans affairs cooperative study in type II diabetes mellitus. Arch Intern Med 1998; 158: 2485-2490 Evidenzklasse Ib
65. Esposito K, Ciotola M, Carleo D et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071-1076 Evidenzklasse Ib
66. Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. British Medical Journal 2007; 335: 497-507 Evidenzklasse Ia
67. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730 Evidenzklasse IV
68. Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. Brit Med J 2005; 330: 1304-1305 Evidenzklasse IV
69. Evans JM, Ogston SA, Emslie-Smith A et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936 Evidenzklasse III
70. FachInfo Actos®: Bundesverband der Pharmazeutischen Industrie: Zusammenfassung der Merkmale des Arzneimittels Actos®. Oktober 2000: 1-3 Evidenzklasse IV
71. Fineman MS, Shen LZ, Taylor K et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-417 Evidenzklasse Ib
72. Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377 Evidenzklasse Ib
73. Fischer S, Hanefeld M, Spengler M et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34-40 Evidenzklasse Ib
74. Fischer S, Patzak A, Rietzsch H et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab 2003; 5: 38-44 Evidenzklasse Ib
75. Fisman EZ, Tenenbaum A, Boyko V et al. Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151-158 Evidenzklasse III
76. Fonseca V, Grunberger G, Gupta S et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diab Care 2003; 26: 1685- 1690 Evidenzklasse Ib
77. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-1702 Evidenzklasse Ib
78. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155 Evidenzklasse Ib
79. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-952 Evidenzklasse Ib
80. Fritsche A, Schmülling RM, Häring HU et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000; 37: 13-18 Evidenzklasse IIa
81. Fritsche A, Schweitzer MA, Häring HU 4001 Study Group. Glimepiride combined with morning insulin glargine bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959 Evidenzklasse Ib
82. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393 Evidenzklasse Ib
83. Gaede P, Andersen HL, Parving HH et al. Effect of a Multifactorial intervention on Mortality in Type Diabetes. N Engl J Med 2008; 358: 580-591 Evidenzklasse Ib
84. Gallwitz B. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2007; 43: 13-25 Evidenzklasse IV
85. Garber A, Duncan T, Goodman A et al. Efficacy of metformin in type-II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 102: 491-497 Evidenzklasse IIa
86. Garber A, Klein E, Bruce S et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diab Obes Metab 2006; 8: 156-163 Evidenzklasse Ib
87. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166-174 Evidenzklasse Ib
88. Garratt KN, Brady PA, Hassinger NL et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124 Evidenzklasse III
89. Gin H, Freyburger C, Boisseau M et al. Effect of metformin on platelet hyperaggregation in the insulin-dependent diabetic. Diabete Metab 1988; 14: 596-600 Evidenzklasse IIa
90. Goldberg RB, Einhorn D, Lucas CP et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21: 1897-1903 Evidenzklasse Ib
91. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554 Evidenzklasse Ib
92. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27: 1761-1773 Evidenzklasse IV
93. Goudswaard AN, Furlong NJ, Rutten GE et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004; 18: SD003418 Evidenzklasse Ia
94. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulfonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20: 239-245 Evidenzklasse III
95. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64 Evidenzklasse Ib
96. Haffner S, Temprosa M, Crandall J et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566- 1572 EvidenzklasseIb
97. Hamann A, Garcia-Puig J, Paul G et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008; 116: 6-13 Evidenzklasse Ib
98. Hamelbeck H, Klein W, Zoltobrocki M et al. Glibenclamide-insulin combination in management of secondary failure of sulfonyl-urea medication. Dtsch Med Wochenschr 1982; 107: 1581-1583 Evidenzklasse IV
99. Hanefeld M, Brunetti P, Schernthaner GH et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diab Care 2004; 27: 141-147 Evidenzklasse Ib
100. Hanefeld M, Pfützner A, Forst T et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Op 2006; 22: 1211-1215 Evidenzklasse IIa
101. Hanefeld M, Göke B. Combining pioglitazone with sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 2000a; 108 (Suppl.2): 256-266 Evidenzklasse IV
102. Hanefeld M, Bouter KP, Dickinson S et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000b; 23: 202-207 Evidenzklasse Ib
103. Hasche H, Mertes G, Bruns C et al. Effects of acarbose treatment in type-2 diabetic patients under dietary training. A multicentre, double blind, place-controlled 2-year study. Diab Nutr Metab 1999; 12: 277-285 Evidenzklasse Ib
104. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569 Evidenzklasse Ib
105. Hermann BL, Schatz H, Pfeiffer A. Kontinuierliche Blutglucosemessung. Der Akuteffekt von Acarbose auf die Blutglucoseschwankungen. Med Klin 1998; 93: 651-655 Evidenzklasse IIb
106. Hermann LS, Schersten B, Bitzen PO et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109 Evidenzklasse Ia
107. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274 Evidenzklasse Ib
108. Hermansen K, Kipnes M, Luo E et al Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745 Evidenzklasse Ib
109. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994; 17: 561-566 Evidenzklasse Ib
110. Holman RR, Cull CA, Turner RC. A randomised double-blind trial of Acarbose in type-2 diabetes shows improved glycemic control over 3years (UKPD Study 44). Diabetes Care 1999; 22: 960-964 Evidenzklasse Ib
111. Holman RR, Thorne KI, Farmer AJ et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730 Evidenzklasse Ib
112. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 35910.1056/NEJMoa0806470 Evidenzklasse Ib
113. Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467-473 Evidenzklasse III
114. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 35710.1056/NEJMoa073394 Evidenzklasse Ib
115. Horton ES, Clinkingbeard C, Gatlin M et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-1665 Evidenzklasse Ib
116. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review). Cochrane Database of systematic Review 2007; Issue 2. Art. No. CD005613, DO1: 10.1002/14651858, CD005613. pub3
117. Huizar JF, Gonzalez LA, Alderman J et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during acute myocardial infarction in diabetics. J Am Coll Cardiol 2003; 42: 1017-1021
118. Jain SK, Nagi DK, Slavin BM et al. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycemic control. Diabet Med 1993; 10: 27-32 Evidenzklasse Ib
119. Jansen JP. Self-moitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006; 22: 671-681 Evidenzklasse Ia
120. Jönsson A, Rydberg T, Ekberg G et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-145 Evidenzklasse IV
121. Jönsson A, Hallengren B, Rydberg T et al. Effects of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001; 3: 403-409 Evidenzklasse IV
122. Johnson JA, Majumdar SR, Simpson SH et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244- 2248 Evidenzklasse III
123. Johnson JA, Simpson SH, Toth EL et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 2005; 22: 497-502 Evidenzklasse IV
124. Johnston P, Sheu WH, Hollenbeck CB et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8 Evidenzklasse IIa
125. Johnston PS, Coniff RF, Hoogwerf BJ et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994; 17: 20-29 Evidenzklasse Ib
126. Jovanovic L, Dailey G, Huang WC et al. Repaglinide in type 2 diabetes: a 24-week fixed dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57 Evidenzklasse Ib
127. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-264 Evidenzklasse Ia
128. Jung HS, Youn BS, Cho YM et al. The effects of rosiglitazone an metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005; 54: 314-320 Evidenzklasse Ib
129. Kado S, Murakami T, Aoki A et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diab Res and Clin Pract 1998; 41: 49-55 Evidenzklasse IIb
130. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburidemonotherapy. N Engl JMed 2006; 355: 2427-2443 Evidenzklasse Ib
131. Kalfhaus J, Berger M. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study. Diabetes Metab 2000; 26: 197-201 Evidenzklasse III
132. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091 Evidenzklasse Ib
133. Kerenyi Z, Samer H, James R et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabet Res Clin Pract 2004; 63: 213-223 Evidenzklasse Ib
134. Kim SG, Ryu OH, Kim HY et al. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Europ J Endocrin 2006; 154: 433-440 Evidenzklasse Ib
135. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002; 4: 145-151 Evidenzklasse III
136. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycaemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-17 Evidenzklasse Ib
137. Klamann A, Sarfert P, Launhardt V et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220-229 Evidenzklasse III
138. Klepzig H, Kober G, Matter C et al. Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446 Evidenzklasse Ib
139. Koivisto VA, Tuominen JA, Ebeling P. Lispro mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999; 22: 459-462 Evidenzklasse IIa
140. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes melllitus. Am Health Syst Pharm 2005; 62: 173-181 Evidenzklasse III
141. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089 Evidenzklasse Ib
142. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes giben thiazolidinediones: a metaanalysis of randomised clinical trials. Lancet 2007; 370: 1129-1136 Evidenzklasse Ia
143. Langenfeld MR, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation 2005; 111: 2525-2531 Evidenzklasse Ib
144. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs and Aging 2000; 17: 411-452 Evidenzklasse IV
145. Landgraf R, Bilo HJ, Müller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55: 165-171 Evidenzklasse Ib
146. Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106: 231-233 Evidenzklasse IIa
147. Lawrence JM, Reid J, Taylor GJ et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diab Care 2004; 27: 41-46 Evidenzklasse Ib
148. Lebovitz H, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Diabet Care 2002; 25: 815-821 Evidenzklasse III
149. Lebowitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diab Res 1998; 6: 132-145 Evidenzklasse Ia
150. Lebowitz HE. Insulin secretagogues: old and new. Diabetes Reviews 1999; 7: 139-153 Evidenzklasse IV
151. Lee TM, Chou TM. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-537 Evidenzklasse Ib
152. Lindsay JR, Duffy NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005; 22: 654-657
153. Linnebjerg H, Kothare PA, Skrivanek Z et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med 2006; 23: 240-245 Evidenzklasse Ib
154. Lotz N, Bachmann W, Ladik T et al. Combination therapy with insulin/sulfonylurea in the long-term therapy of type II diabetes following "secondary failure". Klin Wochenschr 1988; 66: 1079-1084 Evidenzklasse IIa
155. Mäkimattila S, Nikkila K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-412 Evidenzklasse Ib
156. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515 Evidenzklasse Ib
157. Malone JK, Woodworth JR, Arora V et al. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with Type 2 diabetes mellitus. Clin Ther 2000; 22: 222-230 Evidenzklasse Ib
158. Marbury T, Huang W-C, Strange P et al. Repaglinide versus glyburide: a one year comparison trial. Diab Res Clin Pract 1999; 43: 155-166 Evidenzklasse Ib
159. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-1350 Evidenzklasse IIa
160. Martin S, Schneider B, Heinemann L et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006; 49: 271-278 Evidenzklasse IIb
161. Marx N, Froehlich J, Siam L et al. Antidiabetic PPARgamma-Activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Aterioscler Thromb Vasc Biol 2003; 23: 283-288 Evidenzklasse IIa
162. Masoudi FA, Inzucchi SE,Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-590 Evidenzklasse II
163. Matthaei S, Stumvoll M, Kellerer M et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocrine Reviews 2000; 21: 585-618 Evidenzklasse IV
164. Matthaei S, Stumvoll M, Häring HU. Neue Aspekte in der Therapie des Diabetes mellitus Typ 2: Thiazolidindione (Insulinsensitizer). Deutsches Ärzteblatt 2001; 98: A912-A918 Evidenzklasse IV
165. Matthews DR, Charbonnel BH, Hanefeld M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide tometformin in patients with type 2 diabetes: a randomized, comparative study. Diab Metab Res Rev 2005; 21: 167-174 Evidenzklasse Ib
166. May C. Wirksamkeit und Verträglichkeit von einschleichend dosierter Acarbose bei Patienten mit nicht-insulinpflichtigem Diabetes mellitus (Typ-2 Diabetes) unter Sulfonylharnstoffen. Diab Stoffw 1995; 4: 3-8 Evidenzklasse IIa
167. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 2006; 296: 2572-2581 Evidenzklasse Ib
168. Meneilly GS, Rabasa-Lhoret R, Ryan EA et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23: 1162-1167 Evidenzklasse Ib
169. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 30: 9-24 Evidenzklasse IV
170. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204 Evidenzklasse Ib
171. Meyer M, Chudziak F, Schwanstecher C et al. Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes. Br J Pharmacol 1999; 128: 27-34 Evidenzklasse IV
172. Monami M, Luzzi C, Lamanna C et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-482 Evidenzklasse III
173. Moses R, Slobudniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycaemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124 Evidenzklasse Ib
174. Moses RG, Gomis R, Brown Frandsen K et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001; 24: 11-15 Evidenzklasse Ib
175. Mullins P, Sharplin P, Yki-Jarvinen H et al. Negative binomial metaregression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29: 1607-1619 Evidenzklasse Ia
176. Nagasaka S, Aiso Y, Yoshizawa K et al. Comparison of pioglitazone and metformin efficacy using homoeostasis model assessment. Diabet Med 2004; 21: 136-141 Evidenzklasse Ib
177. Nagi D, Yudkin J. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993; 16: 621-629 Evidenzklasse IIa
178. Natali A, Baldeweg S, Toschi E et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diab Care 2004; 27: 1349-1357 Evidenzklasse Ib
179. Natali A, Ferrannini E. Effects ofmetformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49: 434-441 Evidenzklasse Ib
180. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998; 352: 832-833 Evidenzklasse IV
181. Nathan DM, Buse JB, Davidson MB et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972 Evidenzklasse IV
182. Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007a; 50: 259-267 Evidenzklasse Ib
183. Nauck MA, Meininger G, Sheng D et al Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007b; 9: 194-205 Evidenzklasse Ib
184. Nelson P, Poon T, Guan X et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007; 9: 317-326 Evidenzklasse Ib
185. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471 Evidenzklasse Ia
186. Nonaka K, Kakikawa T, Sato A et al. Twelve-week efficacy and tolerability of sitaglipitin, a dipeptidyl peptidase-IV inhibitor, in Japanese patients with T2DM. Diabetes 2006; 55: A129 Evidenzklasse Ib
187. Nonaka K, Kakikawa T, Sato A et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 291-298 Evidenzklasse Ib
188. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117 Evidenzklasse Ib
189. Ong CR, Molyneaux LM, Constantino MI et al. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006; 29: 2361-2364 Evidenzklasse III
190. Övünç K. Effects of glibenclamide, a KATP channel blocker, on warmup phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 2000; 23: 535-539 Evidenzklasse III
191. Olsson J, Lindberg G, Gottsater M et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-560 Evidenzklasse III
192. Orbay E, Sargin M, Sargin H et al. Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes. Endocr J 2004; 51: 521-527 Evidenzklasse IIa
193. Osei K, O'Dorisio TM, Falko JM. Concomitant insulin and sulfonylurea therapy in patients type II diabetes. Effects on glucoregulation and lipid metabolism. Amer J Med 1984; 77: 1002-1009 Evidenzklasse IIa
194. Pan C, Yang W, Barona JP et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441 Evidenzklasse Ib
195. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 1996; 104: 1-9 Evidenzklasse IV
196. Parulkar AA, Pendergrass ML, Granda-Ayala R et al. Nonhypoglycemic effects of thiazolidindiones. Ann Inter Med 2001; 134: 61-71 Evidenzklasse IV
197. Patel A, The ADVANCE Collaborative Group, McMahon S et al. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus. Lancet 2007; 370: 829-840 Evidenzklasse Ib
198. Pavo I, Jermendy G, Varkonyi TT et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645 Evidenzklasse Ib
199. Perriello G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928 Evidenzklasse IIa
200. Pfützner A, Schöndorf T, Seidel D et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metab Clin Exp 2006; 55: 20-25 Evidenzklasse Ib
201. Pfützner A, Forst T. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother 2006; 7: 463-476 Evidenzklasse IV
202. Pistrosch F, Herbrig K, Kindel B et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211 Evidenzklasse Ib
203. Pi-Sunyer FX, Schweizer A, Mills D et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138 Evidenzklasse Ib
204. Ponssen HH, Elte JW, Lehert P et al. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 709-713 Evidenzklasse Ib
205. Pontroli AE, Dino G, Capra F et al. Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure of sulfonyureas. Follow up at two years. Diabete Metab 1990; 16: 323-327 Evidenzklasse III
206. Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7: 467-477 Evidenzklasse Ib
207. Prager R, Schernthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Diabetes 1983; 32: 1083-1086 Evidenzklasse Ib
208. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986; 12: 346-350 Evidenzklasse IIa
209. Pratley RE, Jauffret-Kamel S, Galbreath E et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423-428 Evidenzklasse Ib
210. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356: 2522-2524 Evidenzklasse IV
211. Quatraro A, Consoli G, Ceriello A et al. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab 1986; 12: 315-318 Evidenzklasse IIb
212. Ramachandran A, Snehalatha C, Salini J et al. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes - a study in Indians. J Assoc Physicians India 2004; 52: 459-463 Evidenzklasse Ib
213. Raskin P, Rendell M, Ridde MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232 Evidenzklasse Ib
214. Raskin P, McGill J, Saad MF et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diab Med 2004; 21: 329- 335 Evidenzklasse Ib
215. Raslova K, Bogoev M, Raz I et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201 Evidenzklasse Ib
216. Ratner RE, Maggs D, Nielsen LL et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419-428 Evidenzklasse IIb
217. Rave K, Klein O, Frick AD et al. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006; 29: 1812-1817 Evidenzklasse Ib
218. Raz I, Hanefeld M, Xu L et al Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571 Evidenzklasse Ib
219. Raz I, Chen Y, Wu M et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-550 Evidenzklasse Ib
220. Riddle M, Hart J, Bingham P et al. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 1992; 303: 151-156 Evidenzklasse IIb
221. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators: The treat-to-target trial: trandomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086 Evidenzklasse Ib
222. Ristic S, Byiers S, Foley J et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692-698 Evidenzklasse Ib
223. Ristic S, Bates BC. Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Drugs Today (Barc) 2006; 42: 519-531 Evidenzklasse Ia
224. Roach P, Trautmann M, Anderson J. Lower incidence of nocturnal hypoglycemia with a novel protamine based formulation of insulin lispro. Diabetes 1998; 47: A92
225. Rosenfalck AM, Thorsby P, Kjems L et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41-46 Evidenzklasse Ib
226. Rosenstock J, Brown A, Fischer J et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2050-2055 Evidenzklasse Ib
227. Rosenstock J, Schwartz SL, Clarc Jr CM et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636 Evidenzklasse IIa
228. Rosenstock J, Einhorn D, Hershon K et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257 Evidenzklasse Ib
229. Rosenstock J, Hassman DR, Madder RD et al Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27: 1265-1270 Evidenzklasse Ib
230. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: ameta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955 Evidenzklasse Ia
231. Rosenstock J, Goldstein BJ, Vinik AI et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (> 60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diab Obes Metab 2005; 7: 1-9 Evidenzklasse Ib
232. Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes. Diabetes Care 2006; 29: 554-559 Evidenzklasse Ib
233. Rosenstock J, Brazg R, Andryuk PJ et al Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-1568 Evidenzklasse Ib
234. Rosenstock J, Baron MA, Dejager S et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007a; 30: 217-223 Evidenzklasse Ib
235. Rosenstock J, Baron MA, Camisasca RP et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007b; 9: 175-185 Evidenzklasse Ib
236. Rosenstock J, Davies M, Home PD et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416 Evidenzklasse Ib
237. Rosenstock R, Fonseca V, McGill J et al. Similar Progression of Diabetic Retinopathy with Glargine or NPH Insulin in Type 2 Diabetes. Diabetes 2008; (Suppl.1) 57: A86 Evidenzklasse Ib
238. Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 20: CD002966. Review Evidenzklasse Ia
239. Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; 25: CD002967 Evidenzklasse Ia
240. Sarol JN, Nicodemus NA, Tan KM et al. Self-monitoring of blood glucose as part of a multicomponent therapy among non-insulin requiring type 2 diabetes patients: ameta-analysis (1966-2004). Curr Med Res Pin 2005; 21: 173-184 Evidenzklasse Ia
241. Schatz H, Massi-Benedetti M. Pioglitazone: From Discovery to Clinical Practice. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl. 2): 221-274 Evidenzklasse IV
242. Schernthaner G, Matthews DR, Charvonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076 Evidenzklasse Ib
243. Schernthaner G. Is dyslipidaemia important if we control glycaemia? Atherosclerosis 2005; Supplementum6: 3-10 Evidenzklasse IV
244. Schernthaner G, Schernthaner GH. Metformin - from Devil to Angel. In: Mogensen CEM, ed. Pharmacotherapy of Diabetes Mellitus. New York: Springer; 2007: (in press) Evidenzklasse IV
245. Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res 1996; 28: 413-418 Evidenzklasse IV
246. Schwartz S, Raskin P, Fonseca V et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and exogenous insulin study group. N Engl J Med 1998; 338: 861-866 Evidenzklasse Ib
247. Schweizer A, Couturier A, Foley JE et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med 2007; 24: 955-961 Evidenzklasse Ib
248. Scott R, Wu M, Sanchez M et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-180 Evidenzklasse Ib
249. Seigler DF, Olsson GM, Skyler JS. Morning versus bedtime isophane insulin in type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med 1992; 9: 826-833 Evidenzklasse IIa
250. Shichiri M, Kishikawa H, Ohkubo Y et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21-B29 Evidenzklasse Ib
251. Simpson SH, Majumdar SR, Tsuyuki RT et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169-174 Evidenzklasse III
252. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis. JAMA 2007; 298: 1189-1195 Evidenzklasse Ia
253. Smith SA et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin: insulin ration in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 6048-6053 Evidenzklasse Ib
254. Stenman S, Groop PH, Saloranta C et al. Effects of the combination of insulin and glibencamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 1988; 31: 206-213 Evidenzklasse IIa
255. Stettler C, Allemann S, Jüni P et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38 Evidenzklasse Ia
256. Stocker DJ, Taylor AJ, Langley RW et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007; 153: 445.e1-445.e6 Evidenzklasse Ib
257. St.John-Sutton M, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064 Evidenzklasse Ib
258. Tan M, Johns D, Gonzalez Galvez G et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel group trial. Clin Ther 2004; 26: 680-693 Evidenzklasse Ib
259. Tan MH, Johns D, Strand J et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004; 21: 859-866 Evidenzklasse Ib
260. Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diab Care 2005; 28: 544-550 Evidenzklasse Ib
261. Tanaka Y, Uchino H, Shimuzu T et al. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol 1999; 376: 17-22
262. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effect of Intensive Glucose Lowering in Type 2 Diabetes. N Eng J Med 2008; 358: 2545-2559 Evidenzklasse Ib
263. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Eng J Med 2008; 358: 2560-2572 Evidenzklasse Ib
264. The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986 Evidenzklasse Ib
265. Tiikainen M, Häkkinen AM, Korsheninnikova E et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176 Evidenzklasse Ib
266. Tschritter O, Fritsche A, Gallwitz B et al. Langwirkende Insulinanaloga in der Therapie des Diabetes mellitus Typ 1 und Typ 2. Diabetes und Stoffwechsel 2005; 6: 375-382 Evidenzklasse Ib
267. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes. (UKPDS33). Lancet 1998; 352: 837-853 Evidenzklasse Ib
268. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998; 352: 854-865 Evidenzklasse Ib
269. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22: 751-759 Evidenzklasse Ib
270. Vague PH, Juhan-Vague I, Alessi MC et al. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin, and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57: 326-328 Evidenzklasse IIa
271. Van de Laar FA, Lucassen PL, Akkermans RP et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results of a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163 Evidenzklasse Ia
272. Van Wijk JPH, de Koning EJP, Castro Carbezas M et al. Rosiglitazone improves postprandial triglyzeride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005; 28: 844-849 Evidenzklasse Ib
273. Viswanathan P, Chaudhuri A, Bhatia R et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13: 444-450 Evidenzklasse IIb
274. Wagstaff AJ, Goa KL. Rosiglitazone - a reviewof its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-1837 Evidenzklasse IV
275. Wan Mohamad WB, Tun Fizi A, Ismail RB et al. Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes Res Clin Pract 2000; 49: 93-99 Evidenzklasse III
276. Wascher TC, Schmoelzer I, , Wiegratz A et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005; 35: 551-557 Evidenzklasse II
277. Watanabe I, Tani S, Anazawa T et al. Effect of pioglitazone on arterosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract 2005; 68: 104-110 Evidenzklasse Ib
278. Welschen LM, Bloemendal E, Nijpels G et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a Systematic review. Diabetes Care 2005; 28: 1510-1517 Evidenzklasse Ia
279. Widen E, Erikson J, Groop L. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first degree relatives of patients with NIDDM. Diabetes 1992; 41: 354-358 Evidenzklasse IIa
280. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type-2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomized, placebo-controlled study. Diabetic Medicine 1999; 16: 755-761 Evidenzklasse Ib
281. Woelever TM, Chiasson JL, Josse RG et al. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Diabetes Care 1999; 10: 1612-1618 Evidenzklasse II
282. Wolfenbuttel BH, Sels JP, Huijberts MS. Rosiglitazone. Expert Opin Pharmacother 2001; 2: 467-478 Evidenzklasse IV
283. Wright A, Burden ACF, Paisey RB et al. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336 Evidenzklasse Ib
284. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-γ; agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diab Care 2002; 25: 376-380 Evidenzklasse Ib
285. Yanagawa T, Araki A, Sasamoto K et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 2004; 53: 353-357 Evidenzklasse Ib
286. Yki-Järvinen H, Kauppila M, Kujansuu E et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433 Evidenzklasse Ib
287. Yki-Järvinen H, Rysy L, Nikkiä K et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999; 130: 389-396 Evidenzklasse Ib
288. Yki-Järvinen H, Dressler A, Ziemen M HOE 901 3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-1136 Evidenzklasse Ib
289. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767 Evidenzklasse IV
290. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451 Evidenzklasse Ib
291. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118 Evidenzklasse IV
292. Yki-Järvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369 Evidenzklasse IV
293. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215-222 Evidenzklasse Ib
294. Zhu XX, Pan CY, Li GW et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diab Tech Ther 2003; 5: 33-42 Evidenzklasse Ib
295. Zinman B, Hoogwerf BJ, Duran Garcia S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485 Evidenzklasse Ib